Products

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX® (Varenicline) Compared With Placebo

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

Corporate News & Issues

Pfizer Completes Acquisition of Wyeth

Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabilities and a leading global presence.

Products

Product Shots

Animal Health

PALLADIA™ First Approved Canine Cancer Therapy

On June 3, 2009, Pfizer Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. – PALLADIA™ (toceranib phosphate) – which was developed by Pfizer to treat mast cell tumors in dogs.

Financial

Pfizer Established Products Business Unit

Corporate News & Issues

Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company

Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.

Financial/Research & Development

Pfizer Presents New Opportunities for Global Growth at Analyst Meeting

At a meeting for investment analysts held in New York City on Mar. 5, Pfizer reviewed strategies to accelerate and refocus the company's pipeline and capture new opportunities for global growth. Speaking at the meeting, Pfizer Chairman and CEO Jeff Kindler said: "We have made real changes in how we operate our business - in our structure, culture and leadership - so that we have a much stronger foundation in place for pursuing the many opportunities before us." Kindler continued: "We are delivering and accelerating our pipeline, and we will seize promising growth opportunities spanning geographies, therapeutic areas and products." Kindler and his leadership team outlined their growth strategies including optimizing Pfizer's patent-protected portfolio; generating revenue opportunities from established products; accelerating growth in emerging markets; focusing on continuous improvement and innovation; and investing in complementary businesses.

Corporate News & Issues

Pfizer Discusses Side Effects From Medications

Medicine safety and terminology can be confusing to the general public, according to Pfizer. Dr. Gretchen Dieck, head of Pfizer’s medicine safety unit, says one misconception is the belief that learning of new side effects after a medicine has received approval is a negative. However, according to Dieck, this is not the case. Rather, this is an indication that the drug’s maker is monitoring patient safety information and reporting it to regulators. This system is designed to aid physicians by providing information on a medicine’s risks and benefits and helps better ensure a patient’s safety when taking them. Dieck says the most important step for patients is to read the instructions.

Financial

Pfizer’s Q4 Results Beat Analyst Expectations

Pfizer reported a higher-than-expected fourth quarter 2007 profit totaling an estimated $2.88 billion. While this represents a 70 percent decrease compared to the same period a year prior, Pfizer’s profit margin exceeded expectations due to a one-time after-tax gain of $7.9 billion. In other year-over-year comparisons, the pharmaceutical company also announced a 4 percent increase in revenue totaling $13.1 billion and a rise in its adjusted diluted earnings per share from $0.43 to $0.52. For its full-year 2007 results, Pfizer reported revenue of $48.6 billion and a profit of $8.3 billion.

Products

Pfizer Study Indicates Risk if Switching From Lipitor

Patients who switch from the cholesterol-reducing drug Lipitor to simvastatin, experience a 30 percent increase in risk of cardiovascular problems, according to a Pfizer study. These heart-related issues included strokes, heart attacks, certain types of heart surgeries or death. The study, conducted in the UK, followed 11,520 patients from October 1997 to June 2005. The results were based on 2,511 patients who took Liptor for six months or more and were switched to simvastatin, compared to the 9,009 patients who remained on Lipitor for the same period and then continued on with the medication’s therapy.